Our Journey Beyond Sunset Boulevard
Evidence-based Analysis of Tumor-Targeted Gene- and Immuno-Therapies Shine a Critical Spotlight on “True” Long-Term Cancer-Free Survival
Seiten
2021
IntechOpen (Verlag)
978-1-83969-415-8 (ISBN)
IntechOpen (Verlag)
978-1-83969-415-8 (ISBN)
- Titel nicht im Sortiment
- Artikel merken
The revival of DeltaRex-G (formerly Rexin-G)—the first proactive tumor-hunting/tumor-killing biomedicine of this kind in history—returned active tumor surveillance and a precision-guided “silver bullet” (dnG1 killer gene) to the cancer clinic with “Expanded Access” in 2019. Empowered by US Right-to-Try legislation, while honoring ethical principles of “informed consent,” this unique graphic/picturesque presentation of clinical and translational medicine is intended for postmodern (post-Enlightenment) layman readers, including cancer patients, students, researchers, and future practitioners in the field of precision gene-based medicine. Confronting logical fallacies in popular opinion, the authors present newsworthy, up-to-date clinical research documenting the successful management of refractory metastatic cancers with tumor-targeted gene therapy vectors—validating “pathotropic” (disease-seeking) tumor targeting avant la lettre.
Erscheinungsdatum | 19.06.2021 |
---|---|
Verlagsort | London |
Sprache | englisch |
Maße | 180 x 260 mm |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
ISBN-10 | 1-83969-415-7 / 1839694157 |
ISBN-13 | 978-1-83969-415-8 / 9781839694158 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Handbuch für die Pflegepraxis
Buch | Softcover (2023)
Springer (Verlag)
39,99 €